MARKET

NXTC

NXTC

NextCure
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.04
-0.32
-3.83%
After Hours: 8.04 0 0.00% 16:00 06/11 EDT
OPEN
8.37
PREV CLOSE
8.36
HIGH
8.40
LOW
8.03
VOLUME
157.69K
TURNOVER
--
52 WEEK HIGH
26.93
52 WEEK LOW
7.42
MARKET CAP
221.98M
P/E (TTM)
-3.5240
1D
5D
1M
3M
1Y
5Y
NextCure to Present at the JMP Securities Life Sciences Conference
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in a firesid...
GlobeNewswire · 2d ago
NextCure to Present Trials in Progress Poster for NC410 at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that clinical trial investigator, Mar...
GlobeNewswire · 05/20 00:08
Sofinnova Ventures Inc Buys Eli Lilly and Co, NextCure Inc, Align Technology Inc, Sells ...
GuruFocus News · 05/16 07:25
The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11)
Benzinga · 05/12 12:57
Stocks That Hit 52-Week Lows On Tuesday
    Before 10 a.m. ET Tuesday, 173 stocks hit new 52-week lows.
Benzinga · 05/11 15:05
Analysts Offer Insights on Healthcare Companies: NextCure (NXTC) and Oncternal Therapeutics (ONCT)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on NextCure (NXTC) and Oncternal Therapeutics (ONCT) with
SmarterAnalyst · 05/07 13:15
BRIEF-Nextcure Reports First Quarter 2021 Financial Results
reuters.com · 05/06 22:05
NextCure Q1 EPS $(0.60) Down From $0.33 YoY
NextCure (NASDAQ:NXTC) reported quarterly losses of $(0.60) per share. This is a 281.82 percent decrease over earnings of $0.33 per share from the same period last year.
Benzinga · 05/06 21:54
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NXTC. Analyze the recent business situations of NextCure through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NXTC stock price target is 19.38 with a high estimate of 30.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 143
Institutional Holdings: 18.92M
% Owned: 68.52%
Shares Outstanding: 27.61M
TypeInstitutionsShares
Increased
24
1.20M
New
19
1.79M
Decreased
33
2.20M
Sold Out
11
229.44K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.92%
Pharmaceuticals & Medical Research
-0.72%
Key Executives
Non-Executive Chairman/Independent Director
David Kabakoff
President/Chief Executive Officer/Director
Michael Richman
Chief Financial Officer
Steven Cobourn
Chief Operating Officer
Timothy Mayer
Senior Vice President
Linda Liu
Chief Scientific Officer
Sol Langermann
Other
Han Myint
Independent Director
John Houston
Independent Director
Elaine Jones
Independent Director
Chau Khuong
Independent Director
Garry Nicholson
Independent Director
Stephen Webster
Independent Director
Stella Xu
No Data
About NXTC
Nextcure Inc. is a clinical-stage biopharmaceutical company, which is focused on discovering and developing immunomedicines to treat cancer and other immune-related diseases. The Company uses its functional integrated nextcure discovery in immune oncology (FIND-IO) technology to functional screening approaches for the identification of targets from multiple therapeutic areas, including autoimmunity and neurology, enabling immunomedicine to treat unmet medical needs. Its product pipelines include NC318, a immunotherapeutic against a immunomodulatory target found on a restricted set of myeloid and tumor cells, and NC410, a immunomedicine designed to block an immune regulator expressed on T cells and suppressive antigen-presenting cell populations, including dendritic cell subpopulations.

Webull offers kinds of NextCure Inc stock information, including NASDAQ:NXTC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NXTC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NXTC stock methods without spending real money on the virtual paper trading platform.